GlassScriptPhysician profile
Samuel Luebbert
NPI 1558742908
$3,545.43
in general payments reported to CMS, 2019-2025
29 companies · $318 in 2025
The $318 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $857 · 2021: $597 · 2022: $635 · 2023: $1,100 · 2024: $37.79 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $517.41 | 2020-2025 | Proclaim, Eterna |
| Medtronic USA, INC. | $427.92 | 2020 | |
| Spr Therapeutics, INC | $353.78 | 2023 | Sprint Pns System |
| Si-Bone, INC. | $353.24 | 2021-2023 | |
| Medtronic, INC. | $298.63 | 2022-2024 | Intellis Adaptivestim, Accurian |
| Abbvie INC. | $231.45 | 2022-2025 | |
| Spinal Simplicity, LLC | $196.91 | 2022 | |
| Vertos Medical, INC. | $180.73 | 2021 | |
| Grt US Holding, INC. | $151.11 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $136.61 | 2020-2021 | |
| Boston Scientific Corporation | $88.36 | 2020 | |
| Scilex Pharmaceuticals INC. | $70.99 | 2021 | |
| Biodelivery Sciences International, INC. | $59.73 | 2020-2021 | |
| Pfizer INC. | $57.12 | 2025 | |
| Bioventus LLC | $47.78 | 2021-2023 | Gelsyn-3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.86 | 2022-2025 | Relistor |
| Pacira Pharmaceuticals Incorporated | $42.41 | 2023 | Iovera, Zilretta |
| Arbor Pharmaceuticals, INC. | $35.44 | 2021 | |
| Amgen INC. | $32.04 | 2021 | |
| Mml US, INC. | $29.19 | 2025 | Reactiv8 |
| Nevro Corp. | $29.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $25.67 | 2022 | |
| Mallinckrodt Hospital Products INC. | $24.29 | 2023 | Acthar |
| Ibsa Pharma INC. | $24.25 | 2022 | |
| Avanos Medical | $23.71 | 2023 | Coolief* Cooled Radiofrequency |
| Averitas Pharma INC. | $18.05 | 2025 | Qutenza |
| Lilly USA, LLC | $17.06 | 2022 | |
| Stryker Corporation | $15.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Luebbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.